

# E Michael Lewiecki

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8151558/e-michael-lewiecki-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

249  
papers

13,592  
citations

59  
h-index

111  
g-index

294  
ext. papers

16,157  
ext. citations

4.9  
avg, IF

6.71  
L-index

#	Paper	IF	Citations
249	Denosumab in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 821-31	59.2	931
248	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1532-1543	59.2	725
247	Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. <i>Bone</i> , <b>2008</b> , 43, 222-229	4.7	408
246	Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 75-91	3.5	344
245	Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. <i>American Journal of Medicine</i> , <b>2013</b> , 126, 13-20	2.4	326
244	Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 123-62	3.5	326
243	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. <i>Endocrine Practice</i> , <b>2016</b> , 22, 1-42	3.2	314
242	Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 163-87	3.5	275
241	Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 351-65	5.6	257
240	Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 962-70	6.3	247
239	Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. <i>Osteoporosis International</i> , <b>2017</b> , 28, 1-19	5.3	245
238	Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. <i>Journal of Bone and Mineral Research</i> , <b>2007</b> , 22, 1832-41	6.3	239
237	Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 1315-22	6.3	230
236	Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3580-94	5.6	227
235	Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , <b>2005</b> , 8, 371-8	3.5	215
234	Official positions of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , <b>2004</b> , 7, 1-6	3.5	215
233	Official positions of the international society for clinical densitometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 3651-5	5.6	211

232	Benefits and risks of bisphosphonate therapy for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 2272-82	5.6	190
231	Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 525-35	6.3	176
230	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. <i>Endocrine Practice</i> , <b>2020</b> , 26, 1-46	3.2	164
229	Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 6-16	6.3	160
228	The Pathophysiology and Treatment of Osteoporosis. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 1837-50	3.5	149
227	Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. <i>Clinical Therapeutics</i> , <b>2002</b> , 24, 1871-86	3.5	146
226	Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 4215-22	5.6	140
225	Vertebral Fractures: Clinical Importance and Management. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 221.e1-10	3.1	139
224	A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 3161-9	5.6	138
223	Hip fracture trends in the United States, 2002 to 2015. <i>Osteoporosis International</i> , <b>2018</b> , 29, 717-722	5.3	132
222	Best Practices for Dual-Energy X-ray Absorptiometry Measurement and Reporting: International Society for Clinical Densitometry Guidance. <i>Journal of Clinical Densitometry</i> , <b>2016</b> , 19, 127-40	3.5	131
221	Observations following discontinuation of long-term denosumab therapy. <i>Osteoporosis International</i> , <b>2017</b> , 28, 1723-1732	5.3	125
220	A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 3183-3193	5.6	118
219	Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 4-14	3.5	116
218	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , <b>2016</b> , 22, 1111-8	3.2	115
217	Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. <i>Journal of Clinical Densitometry</i> , <b>2019</b> , 22, 453-471	3.5	112
216	Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 394-402	5.6	111
215	Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 1480-6	6.3	105

214	Skeletal health in long-duration astronauts: nature, assessment, and management recommendations from the NASA Bone Summit. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 1243-55	6.3	97
213	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 3-10	6.3	94
212	Vertebral fracture assessment: the 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 37-46	3.5	91
211	Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 195-201	6.3	90
210	Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. <i>Journal of Clinical Densitometry</i> , <b>2004</b> , 7, 51-64	3.5	88
209	Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2014</b> , 6, 48-57	3.8	87
208	New targets for intervention in the treatment of postmenopausal osteoporosis. <i>Nature Reviews Rheumatology</i> , <b>2011</b> , 7, 631-8	8.1	87
207	A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1335-42	5.6	80
206	Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 1519-28	5.6	79
205	Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 171-80	5.6	79
204	One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. <i>Journal of Bone and Mineral Research</i> , <b>2019</b> , 34, 419-28	6.3	78
203	Nonresponders to osteoporosis therapy. <i>Journal of Clinical Densitometry</i> , <b>2003</b> , 6, 307-14	3.5	76
202	Safety of bisphosphonates in the treatment of osteoporosis. <i>American Journal of Medicine</i> , <b>2009</b> , 122, S22-32	2.4	74
201	Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 2799-808	5.6	73
200	Efficacy and safety of monthly ibandronate in men with low bone density. <i>Bone</i> , <b>2010</b> , 46, 970-6	4.7	71
199	Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX(®) in clinical practice. <i>Journal of Clinical Densitometry</i> , <b>2011</b> , 14, 171-80	3.5	71
198	Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 4671-7	5.6	70
197	Denosumab for the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 461-70	5.5	66

196	Bisphosphonates for the treatment of osteoporosis: insights for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , <b>2010</b> , 1, 115-28	4.9	62
195	Clinical use of serum and urine bone markers in the management of osteoporosis. <i>Current Medical Research and Opinion</i> , <b>2005</b> , 21, 1015-26	2.5	60
194	Safety of long-term bisphosphonate therapy for the management of osteoporosis. <i>Drugs</i> , <b>2011</b> , 71, 791-814	4.4	59
193	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE. <i>Endocrine Practice</i> , <b>2020</b> , 26, 564-570	3.2	59
192	Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 28-32	3.5	58
191	DXA quality matters. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 388-92	3.5	56
190	Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 188-206	3.5	55
189	Special report on the official positions of the International Society for Clinical Densitometry. <i>Osteoporosis International</i> , <b>2004</b> , 15, 779-84	5.3	55
188	Osteoporosis in Crisis: It's Time to Focus on Fracture. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 1391-1394	6.3	54
187	Suicide, guns, and public policy. <i>American Journal of Public Health</i> , <b>2013</b> , 103, 27-31	5.1	53
186	Romosozumab for the treatment of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 255-263	5.4	52
185	Bone densitometry and vertebral fracture assessment. <i>Current Osteoporosis Reports</i> , <b>2010</b> , 8, 123-30	5.4	52
184	Treat-to-target for osteoporosis: is now the time?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 946-53	5.6	51
183	Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States. <i>JBMR Plus</i> , <b>2019</b> , 3, e10192	3.9	49
182	Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. <i>Bone</i> , <b>2007</b> , 40, 843-51	4.7	49
181	Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. <i>Journal of Bone and Mineral Research</i> , <b>2019</b> , 34, 1033-1040	6.3	48
180	Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 298-306	6.3	48
179	Goal-directed treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 433-8	6.3	47

178	Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 1643-6	6.3	46
177	Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 1977-1980	6.3	45
176	Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 1407-1416	6.3	44
175	Common mistakes in the clinical use of bone mineral density testing. <i>Nature Clinical Practice Rheumatology</i> , <b>2008</b> , 4, 667-74		44
174	Review of guidelines for bone mineral density testing and treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , <b>2005</b> , 3, 75-83	5.4	44
173	Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 351-9	3.5	43
172	Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 1353-63	5.6	42
171	Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. <i>Journal of Women's Health</i> , <b>2009</b> , 18, 1615-26	3	40
170	A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1429-39	6.3	40
169	Treatment of osteoporosis with denosumab. <i>Maturitas</i> , <b>2010</b> , 66, 182-6	5	39
168	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. <i>Osteoporosis International</i> , <b>2019</b> , 30, 45-57	5.3	39
167	RANK ligand inhibition with denosumab for the management of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , <b>2006</b> , 6, 1041-50	5.4	38
166	Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. <i>Expert Opinion on Drug Safety</i> , <b>2007</b> , 6, 663-72	4.1	37
165	Tumor-induced osteomalacia: lessons learned. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 773-7		37
164	Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , <b>2019</b> , 22, 501-505	3.5	35
163	Risk communication and shared decision making in the care of patients with osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2010</b> , 13, 335-45	3.5	35
162	New and emerging concepts in the use of denosumab for the treatment of osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2018</b> , 10, 209-223	3.8	35
161	Official Positions for FRAX <sup>®</sup> Bone Mineral Density and FRAX <sup>®</sup> simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX <sup>®</sup> . <i>Journal of Clinical Densitometry</i> , <b>2011</b> , 14, 226-36	3.5	34

160	Prevention and treatment of postmenopausal osteoporosis. <i>Obstetrics and Gynecology Clinics of North America</i> , <b>2008</b> , 35, 301-15, ix	3.3	34
159	Denosumab update. <i>Current Opinion in Rheumatology</i> , <b>2009</b> , 21, 369-73	5.3	33
158	A review of strontium ranelate and its effect on DXA scans. <i>Journal of Clinical Densitometry</i> , <b>2007</b> , 10, 113-9	3.5	33
157	Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. <i>Expert Opinion on Biological Therapy</i> , <b>2011</b> , 11, 117-27	5.4	32
156	Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, 461-471	1.9	31
155	Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. <i>International Journal of Women's Health</i> , <b>2015</b> , 7, 565-80	2.8	31
154	Standards for performing DXA in individuals with secondary causes of osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 47-57	3.5	31
153	Bone density testing in clinical practice. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2006</b> , 50, 586-95		31
152	Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. <i>Menopause</i> , <b>2013</b> , 20, 130-7	2.5	30
151	Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2014</b> , 96, e90	5.6	29
150	Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. <i>Clinical Therapeutics</i> , <b>2008</b> , 30, 605-21	3.5	29
149	Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 681-9	5.5	27
148	Update on romosozumab : a humanized monoclonal antibody to sclerostin. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 697-707	5.4	26
147	Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. <i>Drug, Healthcare and Patient Safety</i> , <b>2011</b> , 3, 79-91	1.6	26
146	More bone density testing is needed, not less. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 739-42	6.3	25
145	The official positions of the International Society for Clinical Densitometry: perceptions and commentary. <i>Journal of Clinical Densitometry</i> , <b>2009</b> , 12, 267-71	3.5	24
144	Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis. <i>Current Osteoporosis Reports</i> , <b>2010</b> , 8, 15-22	5.4	24
143	Sclerostin and skeletal health. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2015</b> , 16, 149-56	10.5	23

142	Managing osteoporosis: challenges and strategies. <i>Cleveland Clinic Journal of Medicine</i> , <b>2009</b> , 76, 457-66	2.8	23
141	Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. <i>Southern Medical Journal</i> , <b>2008</b> , 101, 735-9	0.6	23
140	Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 1663-72	5.9	23
139	New guidelines for the prevention and treatment of osteoporosis. <i>Southern Medical Journal</i> , <b>2009</b> , 102, 175-9	0.6	22
138	Premenopausal bone health assessment. <i>Current Rheumatology Reports</i> , <b>2005</b> , 7, 46-52	4.9	21
137	Emerging drugs for postmenopausal osteoporosis. <i>Expert Opinion on Emerging Drugs</i> , <b>2009</b> , 14, 129-44	3.7	20
136	Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. <i>Calcified Tissue International</i> , <b>2018</b> , 103, 540-545	3.9	20
135	Denosumab: an investigational drug for the management of postmenopausal osteoporosis. <i>Biologics: Targets and Therapy</i> , <b>2008</b> , 2, 645-53	4.4	19
134	Uses and misuses of quantitative ultrasonography in managing osteoporosis. <i>Cleveland Clinic Journal of Medicine</i> , <b>2006</b> , 73, 742-6, 749-52	2.8	19
133	Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. <i>Osteoporosis International</i> , <b>2020</b> , 31, 1299-1304	5.3	18
132	International Society for Clinical Densitometry official positions: Asia-Pacific Region consensus. <i>Journal of Clinical Densitometry</i> , <b>2010</b> , 13, 346-51	3.5	18
131	Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , <b>2021</b> , 24, 3-13	3.5	18
130	T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. <i>Journal of Bone and Mineral Research</i> , <b>2020</b> , 35, 1333-1342	6.3	18
129	Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. <i>IDrugs: the Investigational Drugs Journal</i> , <b>2009</b> , 12, 799-809		18
128	Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 1481-1485	6.3	17
127	Management of osteoporosis. <i>Clinical and Molecular Allergy</i> , <b>2004</b> , 2, 9	3.7	17
126	Adverse effects of media reports on the treatment of osteoporosis. <i>Journal of Endocrinological Investigation</i> , <b>2018</b> , 41, 1359-1364	5.2	17
125	Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women. <i>Journal of Drug Assessment</i> , <b>2019</b> , 8, 25-31	1.5	16



124	Vertebral Fracture Assessment by dual-energy X-ray absorptiometry: insurance coverage issues in the United States. A White Paper of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , <b>2007</b> , 10, 227-38	3.5	16
123	Update on bone density testing. <i>Current Osteoporosis Reports</i> , <b>2005</b> , 3, 136-42	5.4	16
122	FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. <i>Journal of Clinical Densitometry</i> , <b>2011</b> , 14, 223-5	3.5	15
121	Management of skeletal health in patients with asymptomatic primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , <b>2010</b> , 13, 324-34	3.5	15
120	Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 862.e1-862.e7	2.4	14
119	Bone Health ECHO: telementoring to improve osteoporosis care. <i>Women's Health</i> , <b>2016</b> , 12, 79-81	3	14
118	Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2014</b> , 17, 490-5	3.5	14
117	Monoclonal antibodies for the treatment of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 183-96	5.4	14
116	Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. <i>Expert Review of Clinical Pharmacology</i> , <b>2014</b> , 7, 281-91	3.8	14
115	Official positions of the International Society for Clinical Densitometry. <i>Osteoporosis International</i> , <b>2006</b> , 17, 1700-1	5.3	14
114	Treated Osteoporosis Is Still Osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2019</b> , 34, 605-606	6.3	14
113	Osteoporosis: Treat-to-Target. <i>Current Osteoporosis Reports</i> , <b>2017</b> , 15, 103-109	5.4	13
112	DXA: 30years and counting: Introduction to the 30th anniversary issue. <i>Bone</i> , <b>2017</b> , 104, 1-3	4.7	13
111	Emerging anabolic agents in the treatment of osteoporosis. <i>Expert Opinion on Emerging Drugs</i> , <b>2017</b> , 22, 247-257	3.7	13
110	Algorithm for the management of osteoporosis. <i>Southern Medical Journal</i> , <b>2010</b> , 103, 1009-15; quiz 1016.	6.6	13
109	Official positions of the International Society for Clinical Densitometry. <i>Southern Medical Journal</i> , <b>2004</b> , 97, 107-10	0.6	13
108	Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. <i>Archives of Osteoporosis</i> , <b>2018</b> , 13, 85	2.9	12
107	Telementoring: a novel approach to reducing the osteoporosis treatment gap. <i>Osteoporosis International</i> , <b>2017</b> , 28, 407-411	5.3	12

106	Lasofosifene for the prevention and treatment of postmenopausal osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , <b>2009</b> , 5, 817-27	2.9	12
105	In the clinic. Osteoporosis. <i>Annals of Internal Medicine</i> , <b>2011</b> , 155, ITC1-1-15; quiz ITC1-16	8	12
104	Standards and guidelines for technologists performing central dual-energy X-ray absorptiometry. <i>Journal of Clinical Densitometry</i> , <b>2007</b> , 10, 189-95	3.5	12
103	Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 3450-3461	5.6	11
102	Clinical use of denosumab for the treatment for postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 2807-12	2.5	11
101	Diagnostic agreement at the total hip using different DXA systems and the NHANES III database. <i>Journal of Clinical Densitometry</i> , <b>2007</b> , 10, 132-7	3.5	11
100	Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A. Kanis et al. <i>Journal of Clinical Densitometry</i> , <b>2005</b> , 8, 143-4	3.5	11
99	Project ECHO: Telehealth to Expand Capacity to Deliver Best Practice Medical Care. <i>Rheumatic Disease Clinics of North America</i> , <b>2019</b> , 45, 303-314	2.4	10
98	Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, 735-744	1.9	10
97	Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis. <i>Journal of the Endocrine Society</i> , <b>2017</b> , 1, 1428-1434	0.4	10
96	Bone density measurement and assessment of fracture risk. <i>Clinical Obstetrics and Gynecology</i> , <b>2013</b> , 56, 667-76	1.7	10
95	Denosumab--an emerging treatment for postmenopausal osteoporosis. <i>Expert Opinion on Biological Therapy</i> , <b>2010</b> , 10, 467-76	5.4	10
94	Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. <i>Endocrine Practice</i> , <b>2009</b> , 15, 573-9	3.2	10
93	Repeating Vertebral Fracture Assessment: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , <b>2019</b> , 22, 484-488	3.5	9
92	Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , <b>2019</b> , 22, 489-500	3.5	9
91	Consensus on best practice standards for Fracture Liaison Service in the Asia-Pacific region. <i>Archives of Osteoporosis</i> , <b>2018</b> , 13, 59	2.9	9
90	Detection of Atypical Femur Fractures. <i>Journal of Clinical Densitometry</i> , <b>2019</b> , 22, 506-516	3.5	9
89	Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. <i>American Journal of Medicine</i> , <b>2019</b> , 132, e771-e777	2.4	9

88	The role of risk communication in the care of osteoporosis. <i>Current Osteoporosis Reports</i> , <b>2011</b> , 9, 141-8	5.4	9
87	Denosumab in postmenopausal osteoporosis: what the clinician needs to know. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2009</b> , 1, 13-26	3.8	9
86	Denosumab for joints and bones. <i>Current Rheumatology Reports</i> , <b>2009</b> , 11, 196-201	4.9	9
85	Denosumab: a promising drug for the prevention and treatment of osteoporosis. <i>Women's Health</i> , <b>2006</b> , 2, 517-25	3	9
84	Bone Health TeleECHO: a Force Multiplier to Improve the Care of Skeletal Diseases in Underserved Communities. <i>Current Osteoporosis Reports</i> , <b>2019</b> , 17, 474-482	5.4	8
83	Osteoporosis update from the 2010 santa fe bone symposium. <i>Journal of Clinical Densitometry</i> , <b>2011</b> , 14, 1-21	3.5	8
82	Monitoring pharmacological therapy for osteoporosis. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2010</b> , 11, 261-73	10.5	8
81	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. <i>Endocrine Practice</i> , <b>2021</b> , 27, 379-380	3.2	8
80	Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors. <i>Climacteric</i> , <b>2015</b> , 18 Suppl 2, 39-46	3.1	7
79	Imaging technologies for assessment of skeletal health in men. <i>Current Osteoporosis Reports</i> , <b>2013</b> , 11, 1-10	5.4	7
78	The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2015</b> , 24, 324-9	3.5	7
77	Long dosing intervals in the treatment of postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2617-25	2.5	7
76	Impact of using the ultradistal radius region of interest on diagnostic classification. <i>Journal of Clinical Densitometry</i> , <b>2004</b> , 7, 143-52	3.5	7
75	High Cardiorespiratory Fitness Is Associated with Reduced Risk of Low Bone Density in Postmenopausal Women. <i>Journal of Women's Health</i> , <b>2016</b> , 25, 1073-1080	3	7
74	Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. <i>Bone</i> , <b>2020</b> , 134, 115287	4.7	6
73	Stop the war on DXA!. <i>Annals of the New York Academy of Sciences</i> , <b>2018</b> , 1433, 12-17	6.5	6
72	Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, 1074-80	3.5	6
71	Bone density testing: science, the media, and patient care. <i>Current Osteoporosis Reports</i> , <b>2014</b> , 12, 227-9	5.4	6

70	Suicide affects all of us. <i>Lancet, The</i> , <b>2012</b> , 379, 2316-8	4.0	6
69	Bone density testing intervals and common sense. <i>Current Osteoporosis Reports</i> , <b>2012</b> , 10, 217-20	5.4	6
68	2009 Santa Fe Bone symposium. <i>Journal of Clinical Densitometry</i> , <b>2010</b> , 13, 1-9	3.5	6
67	Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. <i>Core Evidence</i> , <b>2010</b> , 4, 13-23	4.9	6
66	The evolution of fracture risk estimation. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 2098-100	6.3	6
65	A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. <i>European Geriatric Medicine</i> , <b>2016</b> , 7, 519-525	3	6
64	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1784-1802	4.7	5
63	The Clinical Utility of Vertebral Fracture Assessment in Predicting Fractures. <i>Journal of Clinical Densitometry</i> , <b>2017</b> , 20, 304-308	3.5	5
62	Denosumab for the treatment of postmenopausal osteoporosis. <i>Women's Health</i> , <b>2009</b> , 5, 15-22	3	5
61	Fracture Risk Assessment in Clinical Practice: T-scores, FRAX, and Beyond. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , <b>2010</b> , 8, 101-112	2.5	5
60	A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 478-84	3.5	5
59	Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint. <i>Journal of Clinical Densitometry</i> , <b>2016</b> , 19, 485-491	3.5	5
58	The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. <i>Osteoporosis International</i> , <b>2019</b> , 30, 71-78	5.3	5
57	Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict. <i>Osteoporosis International</i> , <b>2019</b> , 30, 2401-2406	5.3	4
56	Core principles for fracture prevention: North American Consensus from the National Osteoporosis Foundation, Osteoporosis Canada, and Academia Nacional de Medicina de Mexico. <i>Osteoporosis International</i> , <b>2020</b> , 31, 2073-2076	5.3	4
55	Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries. <i>BMJ Open</i> , <b>2021</b> , 11, e047258	3	4
54	The Rare Bone Disease TeleECHO Program: Leveraging Telehealth to Improve Rare Bone Disease Care. <i>Current Osteoporosis Reports</i> , <b>2020</b> , 18, 344-349	5.4	3
53	Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 902	8	3

52	Osteoporosis update from the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 584-600	3.5	3
51	FRI0289 Denosumab Treatment in Postmenopausal Women with Osteoporosis for Up to 9 Years: Results Through Year 6 of the Freedom Extension. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 529.2-530 <sup>2.4</sup>		3
50	Skeletal Imaging in Primary Hyperparathyroidism <b>2015</b> , 447-454		3
49	New and emerging therapies for osteoporosis. <i>Journal of Osteoporosis</i> , <b>2010</b> , 2010, 318320	2.8	3
48	Is it ethical to use placebos in osteoporosis trials?. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 274-80	3.5	3
47	Pulse-echo Ultrasound Identifies Caucasian and Hispanic Women at Risk for Osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2021</b> , 24, 175-182	3.5	3
46	Estimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX- and Virtual Twin-Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials. <i>JBMR Plus</i> , <b>2020</b> , 4, e10348	3.9	2
45	Clinical Vignettes: Using Non-BMD Measurements in Clinical Practice. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , <b>2016</b> , 14, 50-54	2.5	2
44	Evaluation of the Patient at Risk for Osteoporosis <b>2013</b> , 1481-1504		2
43	A piece of my mind. Time to reconsider. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 1070-1	27.4	2
42	Is denosumab better than alendronate in the treatment of osteoporosis?. <i>Nature Clinical Practice Rheumatology</i> , <b>2009</b> , 5, 72-3		2
41	Augmentation procedures for osteoporotic vertebral fractures--an ongoing experiment or emerging standard of care?. <i>Southern Medical Journal</i> , <b>2006</b> , 99, 449-50	0.6	2
40	Medications don't work if patients don't take them. <i>Southern Medical Journal</i> , <b>2007</b> , 100, 1190-1	0.6	2
39	Bone Health TeleECHO for Orthopedists and Rheumatologists <b>2017</b> , 7,		2
38	Operationalizing Treat-to-Target for Osteoporosis. <i>Endocrinology and Metabolism</i> , <b>2021</b> , 36, 270-278	3.5	2
37	Effective communication regarding risk of fracture for individuals at risk of fragility fracture: a scoping review. <i>Osteoporosis International</i> , <b>2021</b> , 1	5.3	2
36	Teriparatide: Label changes and identifying patients for long-term use. <i>Cleveland Clinic Journal of Medicine</i> , <b>2021</b> , 88, 489-493	2.8	2
35	Evaluation of the osteoporosis patient <b>2021</b> , 1475-1500		2

34	Romozosumab and antiresorptive treatment: the importance of treatment sequence.. <i>Osteoporosis International</i> , <b>2022</b> , 1	5.3	2
33	Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 901	8	1
32	Kyphosis and vertebral fractures: what do we know now?. <i>Aging Health</i> , <b>2009</b> , 5, 483-487		1
31	Is alendronate therapy cost-effective for postmenopausal osteopenia?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2005</b> , 1, 74-5		1
30	T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romozosumab vs Alendronate Treatment in the ARCH Trial <b>2020</b> , 29,		1
29	Phytoestrogens and their role in the management of postmenopausal osteoporosis. <i>Southern Medical Journal</i> , <b>2009</b> , 102, 111-2	0.6	1
28	Preventing fractures in diabetic dialysis patients. <i>International Journal of Endocrinology and Metabolism</i> , <b>2012</b> , 10, 640-1	1.8	1
27	Assessment of Skeletal Strength: Bone Density Testing and Beyond. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2021</b> , 50, 299-317	5.5	1
26	The role of osteoanabolic agents in the management of patients with osteoporosis. <i>Postgraduate Medicine</i> , 1-11	3.7	1
25	Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 1900-1901	6.3	0
24	Fractures While Walking Leashed Dogs. <i>JAMA Surgery</i> , <b>2019</b> , 154, 1078	5.4	0
23	Evaluating Patients for Secondary Causes of Osteoporosis.. <i>Current Osteoporosis Reports</i> , <b>2022</b> , 20, 1	5.4	0
22	Racial Disparities and Inequalities in the Management of Patients With Osteoporosis.. <i>Orthopaedic Nursing</i> , <b>2022</b> , 41, 125-134	0.9	0
21	The current role of telehealth in the management of patients with osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> ,	4.1	0
20	SAT0487 Denosumab (DMAB) Effect on Bone Histology and Histomorphometry in Men with Low Bone Mineral Density (BMD). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 769.2-769	2.4	
19	Firearm-related injury and death in the United States. <i>Annals of Internal Medicine</i> , <b>2015</b> , 163, 323-4	8	
18	SAT0463 Effect of Eight Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Five-Year Results from the Freedom Extension. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 761.2-761	2.4	
17	Is it time for physicians to focus on the public health threat of gun violence?. <i>Annals of Internal Medicine</i> , <b>2013</b> , 158, 851-2	8	

16	Pharmacologic therapy to reduce fracture risk: comment on the clinical practice guidelines of the ACP. <i>Nature Reviews Rheumatology</i> , <b>2009</b> , 5, 120-1	8.1
15	Prevention of osteoporotic fractures. <i>Aging Health</i> , <b>2006</b> , 2, 649-659	
14	Recommendations regarding individuals in whom bone densitometry should be performed: comment on the article by van Staa et al. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 2715-6	
13	Update on osteoporosis. <i>Women's Health</i> , <b>2005</b> , 1, 23-5	3
12	Update on bone density testing. <i>Current Osteoporosis Reports</i> , <b>2005</b> , 3, 136-142	5.4
11	Osteoporosis Treatment Success and Failure <b>2021</b> , 185-195	
10	Osteoporosis Management with Focus on Spine <b>2021</b> , 61-92	
9	Skeletal health prognostications. <i>Southern Medical Journal</i> , <b>2006</b> , 99, 105-6	0.6
8	Do Phytoestrogens Have a Role in the Management of Postmenopausal Osteoporosis?. <i>Southern Medical Journal</i> , <b>2008</b> , 101, 2	0.6
7	Denosumab: Mechanisms and Therapeutic Effects in the Treatment of Osteoporosis. <i>Contemporary Endocrinology</i> , <b>2020</b> , 309-322	0.3
6	Integrated Clinical View on Long-Term Management of Patients with Osteoporosis <b>2016</b> , 309-320	
5	Monitoring Therapy for Osteoporosis 227-238	
4	Standard Techniques of Bone Mass Measurement in Adults <b>2018</b> , 252-259	
3	Strontium Ranelate and Calcitonin <b>2018</b> , 573-578	
2	Letter to the Editor from Dreyer, et al: "Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e1920-e1921	5.6
1	Glucocorticoid-Induced Osteoporosis <b>2022</b> , 285-290	